CLOs on the Move

H.D. Smith Wholesale Drug Co.

www.hdsmith.com

 
Headquartered in Springfield, Illinois, H. D. Smith is among the largest national full-line, full-service wholesalers providing a complete line of pharmaceuticals, OTCs, HBAs, home healthcare products, durable medical equipment, seasonal merchandise and a wide array of marketing programs to retail pharmacies, regional chains and health systems.
  • Number of Employees: 250-1000
  • Annual Revenue: $500M-1 Billion
  • www.hdsmith.com
  • 3063 Fiat Ave
    Springfield, IL USA 62703
  • Phone: 217.753.1688

Executives

Name Title Contact Details

Similar Companies

Hyaluron

Hyaluron is a Burlington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quantom Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new drug class for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure.

biopharmservices

biopharmservices is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Macrocure

Macrocure Ltd. is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Our novel approach is to treat and close chronic and other hard-to-heal wounds by injecting the human body`s own wound healing and regenerative components directly into the wound itself.

Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.